Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

5.25USD
12 Dec 2018
Change (% chg)

-- (--)
Prev Close
$5.25
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
140,419
52-wk High
$14.62
52-wk Low
$4.86

Latest Key Developments (Source: Significant Developments)

Orbimed Advisors Reports 4.69 Pct Stake In Adaptimmune Therapeutics As Of Sept 7
Wednesday, 10 Oct 2018 

Oct 10 (Reuters) - Orbimed Advisors LLC: :ORBIMED ADVISORS LLC SAYS CAUSED OPI V TO BUY SHARES OF ADAPTIMMUNE THERAPEUTICS FOR PURPOSE OF INVESTMENT IN CO - SEC FILING.ORBIMED ADVISORS LLC SAYS CAUSED OPI V TO BUY SHARES OF ADAPTIMMUNE NOT WITH INTENTION OF ACQUIRING CONTROL OF ADAPTIMMUNE ON BEHALF OF OPI V.ORBIMED ADVISORS LLC REPORTS 4.69 PERCENT STAKE IN ADAPTIMMUNE THERAPEUTICS PLC AS OF SEPT 7.ORBIMED ADVISORS LLC PREVIOUSLY REPORTED 5.44 PERCENT STAKE IN ADAPTIMMUNE THERAPEUTICS PLC AS OF MARCH 27.  Full Article

Adaptimmune Announces Favorable Review Of Safety From One Billion Cell Dose Cohort In Mage-A10 Spear T-Cell Study
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE ANNOUNCES FAVORABLE REVIEW OF SAFETY FROM ONE BILLION CELL DOSE COHORT IN MAGE-A10 SPEAR T-CELL STUDY AND INITIATION OF THIRD DOSING COHORTS.ADAPTIMMUNE THERAPEUTICS PLC - SAFETY REVIEW COMMITTEE ENDORSED DOSE ESCALATION TO THIRD DOSE COHORTS IN BOTH MAGE-A10 PILOT STUDIES.ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN REPORTED.  Full Article

Adaptimmune Announces First Patient To Receive One Billion Target Cell Dose After Positive Safety Data
Monday, 4 Jun 2018 

June 4 (Reuters) - Adaptimmune Therapeutics PLC ::ADAPTIMMUNE ANNOUNCES FIRST PATIENT TO RECEIVE ONE BILLION TARGET CELL DOSE AFTER POSITIVE SAFETY DATA FROM PILOT STUDY WITH MAGE-A4 SPEAR T-CELLS.ADAPTIMMUNE THERAPEUTICS - NO EVIDENCE OF OFF-TARGET TOXICITY AT 100 MILLION CELLS FOR SECOND WHOLLY OWNED ASSET.ADAPTIMMUNE THERAPEUTICS PLC - SYNOVIAL SARCOMA AND MRCLS ADDED TO SEVEN SOLID TUMORS ALREADY IN MAGE-A4 BASKET STUDY.ADAPTIMMUNE THERAPEUTICS PLC - WILL START TREATING PATIENTS WITH TARGET DOSE OF ONE BILLION TRANSDUCED MAGE-A4 SPEAR T-CELLS IN ONGOING BASKET STUDY.  Full Article

Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc ::ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING.ADAPTIMMUNE THERAPEUTICS - AGREEMENT IS FOR TERM OF 5 YEARS WITH EARLIER TERMINATION AVAILABLE TO BOTH PARTIES ON PROVISION OF 12 MONTHS' NOTICE.ADAPTIMMUNE THERAPEUTICS PLC - AGREEMENT WILL ENABLE CO TO HAVE ITS OWN DEDICATED VECTOR MANUFACTURING SPACE IN UK.ADAPTIMMUNE - AGREEMENT TO ENSURE VECTOR SUPPLY PRODUCTION BEYOND 2020 FOR ONGOING STUDIES WITH 3 SPEAR T-CELL THERAPIES, MAGE-A4, MAGE-A10 AND AFP.  Full Article

Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Adaptimmune Therapeutics Plc :::ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE.ADAPTIMMUNE THERAPEUTICS PLC - NO EVIDENCE OF TOXICITY RELATED TO OFF-TARGET BINDING OR ALLOREACTIVITY HAS BEEN OBSERVED.ADAPTIMMUNE - IN NSCLC STUDY, THERE HAS BEEN ONE SERIOUS ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME, A GRADE 4 EVENT THAT RESOLVED WITH TREATMENT.ADAPTIMMUNE THERAPEUTICS PLC - ADVERSE EVENT OF CYTOKINE RELEASE SYNDROME IN NSCLC STUDY LED TO COHORT 1 EXPANSION FROM 3 TO 6 PATIENTS.  Full Article

Adaptimmune Therapeutics Q3 loss per share $0.00
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Adaptimmune Therapeutics Plc :Adaptimmune reports third quarter 2017 financial results and business updates.Q3 revenue $27.2 million versus $2.4 million.Q3 revenue view $6.3 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.00.Adaptimmune- existing cash, cash equivalents, securities, income from GSK on transition of NY-ESO program to fund operating plan through to early 2020​.  Full Article